CN103483282B - Phenyl-substituted triazole amide compounds and application - Google Patents
Phenyl-substituted triazole amide compounds and application Download PDFInfo
- Publication number
- CN103483282B CN103483282B CN201310418209.5A CN201310418209A CN103483282B CN 103483282 B CN103483282 B CN 103483282B CN 201310418209 A CN201310418209 A CN 201310418209A CN 103483282 B CN103483282 B CN 103483282B
- Authority
- CN
- China
- Prior art keywords
- compound
- diabetes
- ppar
- present
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
Abstract
The invention relates to the field of drugs relevant to the diabetes, in particular to compounds of triazole amide structures, a preparation method and an application in the aspect of treating the diabetes. The compounds have the general formula I, play a role in treating the diabetes and can be used as a PPAR agonist. The perssad definition is mentioned in the specification.
Description
Technical field
The present invention relates to the pharmaceutical field relevant to diabetes.Specifically, the present invention relates to peroxisome proliferator-activated property acceptor (PPAR) agonist of the medicative class of diabetes containing triazolylamide skeleton, its preparation method and the pharmaceutical composition containing them.
Background technology
Diabetes are diseases of Patients' rights blood sugar capability deteriorates, and patient loses ability insulin action being made to appropriate reaction to some extent.In diabetes, major part is type ii diabetes (i.e. non insulin dependent diabetes), account for 80%-90%, research finds, the insulin resistant of peripheral tissues's (comprising skeletal muscle, liver and fatty tissue etc.) plays a part very important in the generation, development of type ii diabetes.Having introduced a class at present makes patient recover responsive class medicine, i.e. an insulin sensitizers to own insulin, returns to normally to make Regular Insulin and triglyceride level.In the treatment of research diabetes, peroxisome proliferator-activated property acceptor (PPARs) becomes desirable target, it is one of nuclear receptor superfamily member, several genes can be regulated and controled express simultaneously, take part in Adipocyte Differentiation, lipid metabolism adjustment and increase the physiological processs such as insulin sensitivity.There is three types in PPAR family: PPAR α, PPAR β (being also PPAR δ) and PPAR γ.PPAR α relates to the β-oxidation stimulating lipid acid, also relate to control HDL cholesterol levels, play an important role in Liver lipids metabolism, and PPAR γ acceptor relates to Adipocyte Differentiation program and must activate, insulin resistant can be improved and improve insulin sensitivity (Yang Jun, Zou Xiulan, PPAR α/γ double excitations machine and diabetes B, Medical review, 2008,14 (16): 2492-2496).PPAR γ is considered to the main molecules target of glitazone insulin sensitizers, although glitazone compound is the active drug for the treatment of type ii diabetes, but the side effect of this compounds clearly, such as serious toxin for liver type, body weight increase and anaemia, this mainly glitazone be the main of PPAR γ or full agonist (N A Jie, sieve D is thorough, her Feng of S, CN101098865A).Therefore, the dual agonists of PPAR α and PPAR γ just can alleviate the side effect even eliminating glitazone PPAR gamma agonist, except making blood sugar and Regular Insulin normalizing, also has the effect reducing blood fat and suppress cardiovascular complication.
The invention discloses the dual agonists of a class triazolylamide compounds as PPAR α and PPAR γ, the medicine that these inhibitor may be used for the medicine, particularly non insulin dependent diabetes preparing treatment diabetes lays the foundation.
Summary of the invention
An object of the present invention is the shortcoming and defect overcoming prior art, provide one to have excellent activity, there is the compound of general formula I.
Another object of the present invention is to provide preparation and has the compound of general formula I and the method for salt and ester thereof.
Another object of the present invention is to provide the application of compound in treatment diabetes containing general formula I.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula I has following structural formula:
Wherein,
R
1be selected from H, methyl, ethyl;
R
2be selected from the alkyl of H, C1-C5.
Preferred following compound of Formula I,
R
1be selected from H, methyl, ethyl;
R
2be selected from the alkyl of H, C1-C3.
The compound that preferred the present invention has general formula I is as follows:
Compound of Formula I of the present invention is synthesized by following steps:
Compd A and B react in the presence of an inorganic base, obtain Compound C; Compound C PBr
3process obtains Compound D, and D and E is obtained by reacting Compound I in the presence of a base.
The pharmacy acceptable salt of formula I of the present invention comprises, but be not limited to and various mineral acid, such as, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid etc., or organic acid, the pharmacy acceptable salt that such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, toxilic acid, amino acid etc. generate.
Compound of Formula I of the present invention has the double excitations effect of PPAR α and PPAR γ, can be used as effective constituent for the preparation of the medicine of diabetes aspect can lose weight and increase and suppress cardiovascular complication disease.The activity of compound of Formula I of the present invention is by hypoglycemic in body and fall blood cholesterol levels and triglyceride level model is verified.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 20mg-400mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.These situations comprise: the physical state of patient, route of administration, age, body weight, individual reaction to medicine, the severity etc. of symptom.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
Embodiment 1
1.37g (10mmol) compd A-1 and 1.24g (10mmol) compd B-1 are dissolved in 10mL DMF, add 4.15g (30mmol) K
2cO
3, then spend the night at 120 DEG C of stirred under nitrogen atmosphere.In the slightly cold rear impouring 100mL frozen water of reaction mixture, stir, regulate pH=3-4 with concentrated hydrochloric acid, with the dichloromethane extraction of 50mL × 3, merge extraction phase, once, anhydrous sodium sulfate drying, boils off solvent at Rotary Evaporators and obtains a resistates in salt water washing, then column chromatography purification, obtain the sterling of C-1, ESl-MS, m/z=199 ([M+NH4]
+).
1.45g (8mmol) Compound C-1 is dissolved in the toluene of 10mL drying, slowly stir under ice-water bath cooling, slowly drip the solution that methylene dichloride that 2.71g (10mmol) PBr3 is dissolved in 2mL drying is made, dropwising rear reaction mixture at room temperature to stir after half an hour in impouring 100mL frozen water, stir, with the dichloromethane extraction of 50mL × 3, merge extraction phase, salt water washing once, anhydrous sodium sulfate drying, boil off solvent at Rotary Evaporators and obtain a resistates, then column chromatography purification, obtain the sterling of D-1, ESI-MS, m/z=258 ([M+NH4]
+).
1.22g (5mmol) Compound D-1 and 0.96g (5mmol) E-1 are dissolved in 5mL MeCN, stir, add 2.07g (15mmol) K
2cO
3, continue under room temperature to stir until raw material consumption complete (12-24 hour).In reaction mixture impouring 100mL frozen water, stir, regulate pH=3-4 with concentrated hydrochloric acid, with the dichloromethane extraction of 50mL × 3, merge extraction phase, once, anhydrous sodium sulfate drying, boils off solvent at Rotary Evaporators and obtains a resistates in salt water washing, then column chromatography purification, obtain the sterling of I-1, faint yellow solid, fusing point 183-186 DEG C; ESI-MS, m/z=369 ([M+NH4]
+).
Embodiment 2-6
With reference to the method for embodiment 1, prepare the compound that the general formula shown in following table is I.
Embodiment 7
Sample is mixed with the suspension of 5mg/mL concentration with 1% Xylo-Mucine, and administration volume is 0.4mL/20g body weight, is equivalent to 100mg/kg dosage.
Healthy ICR mouse, male and female half and half, body weight 20-24g, meets primary standard.Animal fasting 16 hours, gavage gives the dextrose in saline solution of testing compound 15 minutes pneumoretroperitoneum injection 2g/kg, after modeling, 0.5h, 1h, 1.5h and 2h timing is taken kapillary and is got blood from mouse ball rear vein beard, centrifugation serum, with each time point serum glucose level of determination of glucose oxidase.Blank mouse neither gives glucose and does not also give testing compound, and model mice only gives glucose and do not give testing compound.
Data as can be seen from upper form, each administration all significantly can strengthen the mouse blood sugar dosis tolerata that glucose causes.
Embodiment 8
Sample is mixed with the suspension of 5mg/mL concentration with 1% Xylo-Mucine, and administration capacity is 0.4mL/20g body weight, is equivalent to 100mg/kg dosage.
Healthy Wister rat, male and female half and half, about body weight 300g, meets primary standard.Animal feeds 30 days with high lipid food, measure cholesterol in serum and content of triglyceride, with cholesterol and content of triglyceride for standard random packet, after animal grouping, gavage gives testing compound 7 days continuously, fasting 12 hours before last administration, after medicine, 1h kapillary gets blood from rat ball rear vein beard, centrifugation serum, measures serum cholesterol and content of triglyceride with cholesterol and Triglyceride Reagent box.
Cholesterol level (g/dl)
Content of triglyceride (g/dl)
The data declaration of above-mentioned two tables, compound of the present invention can effectively reduce cholesterol and triglyceride level.
Claims (2)
1. following formula: compound:
2. the purposes of compound described in claim 1 in preparation treatment diabetes medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310418209.5A CN103483282B (en) | 2013-09-03 | 2013-09-03 | Phenyl-substituted triazole amide compounds and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310418209.5A CN103483282B (en) | 2013-09-03 | 2013-09-03 | Phenyl-substituted triazole amide compounds and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103483282A CN103483282A (en) | 2014-01-01 |
| CN103483282B true CN103483282B (en) | 2015-04-22 |
Family
ID=49823931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310418209.5A Expired - Fee Related CN103483282B (en) | 2013-09-03 | 2013-09-03 | Phenyl-substituted triazole amide compounds and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103483282B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108727208B (en) * | 2017-03-07 | 2020-06-30 | 天津键凯科技有限公司 | Linker compound, polyethylene glycol-linker conjugate and derivative thereof, and polyethylene glycol-linker-drug conjugate |
| CN109589415B (en) | 2017-09-30 | 2022-02-18 | 天津键凯科技有限公司 | Conjugate of polyethylene glycol-polypeptide and protein medicine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060100235A1 (en) * | 2003-04-11 | 2006-05-11 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| US7507832B2 (en) * | 2003-12-22 | 2009-03-24 | Eli Lilly And Company | Triazole PPAR modulators |
| CN1934095A (en) * | 2004-03-08 | 2007-03-21 | 惠氏公司 | Ion channel modulators |
| EP1730124A4 (en) * | 2004-03-26 | 2009-04-01 | Amphora Discovery Corp | Certain triazole-based compounds, compositions, and uses thereof |
| JP2007210929A (en) * | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | Medicine containing urea compound |
-
2013
- 2013-09-03 CN CN201310418209.5A patent/CN103483282B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103483282A (en) | 2014-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103304500B (en) | Novel anti-diabetic compound, as well as preparation method and application thereof | |
| TWI830262B (en) | Use of clemizole compounds for prevention and treatment of liver cancer | |
| CN103304501B (en) | Anti-diabetic compound, as well as preparation method and application thereof | |
| JPS5843996A (en) | Stable s-adenosylmethionine salts, manufacture and therapeutical composition containing them as active components | |
| JP2022503890A (en) | A salt formed by 2- (1-acyloxy-N-pentyl) benzoic acid and a basic amino acid or aminoguanidine, and a method and use thereof. | |
| CN103483282B (en) | Phenyl-substituted triazole amide compounds and application | |
| JP2021523934A (en) | Aminopyrazine and related compounds useful as mitochondrial deconjugation agents | |
| WO2021204197A1 (en) | Application of acridinedione compound in preparation of anti-diabetic drugs | |
| CN103467398B (en) | Triazole amide compounds, and preparation method and application thereof in resisting diabetes | |
| CN106317068A (en) | C, O-spiro aryl glycoside compound and preparation and application thereof | |
| CN103483281B (en) | Triazole amide compound and preparing method and antidiabetic function thereof | |
| CN103304498B (en) | Anti-diabetic compound, as well as preparation method and application thereof | |
| CN103304504B (en) | Anti-diabetic compound, as well as preparation method and application thereof | |
| CN103467399B (en) | Triazole amide compounds, and preparation method and application thereof | |
| CN103554043B (en) | Phenyl-substituted triazole amide compounds and application | |
| CN103467407B (en) | Tetrazole carboxylic acid compounds and application thereof | |
| CN103467408B (en) | Tetrazole carboxylic acid compounds and application thereof | |
| CN103467409B (en) | Substituted tetrazole carboxylic acid compounds and application thereof | |
| Tang et al. | Structure–activity relationship and hypoglycemic activity of tricyclic matrines with advantage of treating diabetic nephropathy | |
| CN103467406B (en) | Halogen-substituted tetrazole carboxylic acid compounds, and preparation method and application thereof | |
| CN103304502B (en) | Anti-diabetic compound, as well as preparation method and application thereof | |
| CN103304503B (en) | Anti-diabetic compound, as well as preparation method and application thereof | |
| CN103304499B (en) | Anti-diabetic compound, as well as preparation method and application thereof | |
| CN108623555B (en) | Benzoxel compound, preparation method thereof, pharmaceutical composition and application thereof | |
| CN103626722B (en) | Nitric oxide donator type Hypoglycemics, Preparation Method And The Use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150422 Termination date: 20160903 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |